SCHEMBL5574402

SCHEMBL5574402

O=[N+]([O-])c1cc2c3c(c1)CCc1cccc(c1-3)CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
LMNA P02545 3/20 0.50
KMT2A Q03164 4/20 0.45
MAPT P10636 4/20 0.45
MEN1 O00255 3/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 7/20 0.44
ALOX15 P16050 2/20 0.44
CYP3A4 P08684 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 2/20 0.42
ACHE P22303 1/20 0.42
HPGD P15428 1/20 0.42
ADRA2A P08913 1/20 0.42
PNMT P11086 1/20 0.42
CYP19A1 P11511 1/20 0.41
HSP90AA1 P07900 1/20 0.41
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
CES2 O00748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376486 0.78 TDP1 (0.49) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL9452635 0.75 ACHE (0.46) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL18538297 0.73 ALDH1A1 (0.48) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL9483063 0.72 PNMT (0.65) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL30709850 0.72 PNMT (0.65) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL149965 0.72 TSHR (0.44) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL29388679 0.72 TSHR (0.44) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL19101365 0.72 TYMS (0.50) TSHRLMNAKMT2AMAPTMEN1
SCHEMBL1527540 0.72 PTPRC (0.54) LMNAKMT2AMAPTMEN1ALDH1A1
SCHEMBL31456586 0.72 PTPRC (0.54) LMNAKMT2AMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7170089-B2 (4,5,9,10-Tetrahydro-pyren-2-yl)-carbamic acid 4-(2-methylsulfanyl-alkyl)-3,5-dinitro-benzyl ester, method of synthesizing thereof, and molecular electronic device using the same ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) 2007-01-30 US claimed
US-20060138409-A1 (4,5,9,10-Tetrahydro-pyren-2-yl)-carbamic acid 4-(2-methylsulfanyl-alkyl)-3,5-dinitro-benzyl ester, method of synthesizing thereof, and molecular electronic device using the same LEE HYOYOUNG 2006-06-29 US claimed
US-20050012092-A1 (4,5,9,10-Tetrahydro-pyren-2-yl)-carbamic acid 4-(2-methylsulfanyl-alkyl)-3,5-dinitro-benzyl ester, method of synthesizing thereof, and molecular electronic device using the same INTELLECTUAL DISCOVERY CO., LTD. (KR) 2005-01-20 US claimed
US-7170089-B2 (4,5,9,10-Tetrahydro-pyren-2-yl)-carbamic acid 4-(2-methylsulfanyl-alkyl)-3,5-dinitro-benzyl ester, method of synthesizing thereof, and molecular electronic device using the same ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) 2007-01-30 US disclosed
US-20060138409-A1 (4,5,9,10-Tetrahydro-pyren-2-yl)-carbamic acid 4-(2-methylsulfanyl-alkyl)-3,5-dinitro-benzyl ester, method of synthesizing thereof, and molecular electronic device using the same LEE HYOYOUNG 2006-06-29 US disclosed
US-7053235-B2 (4,5,9,10-Tetrahydro-pyren-2-yl)-carbamic acid 4-(2-methylsulfanyl-alkyl)-3,5-dinitro-benzyl ester, method of synthesizing thereof, and molecular electronic device using the same ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) 2006-05-30 US disclosed
US-20050012092-A1 (4,5,9,10-Tetrahydro-pyren-2-yl)-carbamic acid 4-(2-methylsulfanyl-alkyl)-3,5-dinitro-benzyl ester, method of synthesizing thereof, and molecular electronic device using the same INTELLECTUAL DISCOVERY CO., LTD. (KR) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060138409-A1 (4,5,9,10-Tetrahydro-pyren-2-yl)-carbamic acid 4-(2-methylsulfanyl-alkyl)-3,5-dinitro-benzyl ester, method of synthesizing thereof, and molecular electronic device using the same KDM4E, KDM4B, KDM4D TSHR 4288/4885LMNA 2664/4885KMT2A 109/4885
US-20050012092-A1 (4,5,9,10-Tetrahydro-pyren-2-yl)-carbamic acid 4-(2-methylsulfanyl-alkyl)-3,5-dinitro-benzyl ester, method of synthesizing thereof, and molecular electronic device using the same KDM4E, KDM4B, KDM4D TSHR 4288/4885LMNA 2664/4885KMT2A 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.